Scientific Program

Conference Series Ltd invites all the participants across the globe to attend 10th World Congress on Cardiology Amsterdam, Netherlands.

Submit your Abstract
or e-mail to

cardiology@theexpertsmeet.com

Scientific Program Day 1

Day 1 :

Keynote Forum

William J. Rowe

Former Assistant Clinical Professor of Medicine, Medical University of Ohio at Toledo,USA

Keynote: Hypertension risk from iron brake particulate matter
Conference Series Cardiology-2020 International Conference Keynote Speaker William J. Rowe photo
Biography:

William J. Rowe M.D. FBIS (Fellow British Interplanetary Society), FACN (Fellow American College of Nutrition, Retired Fellow Royal Society of Medicine), is a board certified specialist in Internal Medicine. He received his M.D. at the University of Cincinnati and was in private practice in Toledo, Ohio for 34 years. This triggered a 20 year pursuit of the cardiovascular complications of Space flight. He has published in LANCET that extraordinary, unremitting endurance exercise can injure a perfectly normal heart. Of only 4 space syndromes, he has published 2: "The Apollo 15 Space Syndrome" and "Neil Armstrong Syndrome." 

Abstract:

Of 12 moon walkers, James Irwin on day after return from Apollo 15 mission, showed extraordinary bicycle ( B) stress test (ST) hypertension ( 275/125) after 3 minutes exercise; supervising > 5000  maximum treadmill  ST, author never witnessed ST- blood pressure approaching this level.  Symptom-limited maximum B stress test showed “cyanotic fingernails”; possibly venous blood trapped peripherally, supporting author’s “Apollo 15 Space Syndrome,” postulating that severe fingertip pain during space walks, triggered by plasma fluid, trapped distally;  mechanism could be related to endothelial dysfunction, providing “silent ischemia” warning.  Neil Armstrong returned to Earth with severe diastolic hypertension  ( 160/135), consistent with ischemic left ventricular dysfunction; 50 mm increase in comparison with resting  BP 110/85. With inhalation of lunar dust, brought into habitat on space suit, with high lunar iron (I) this dust inhalation, along with reduced (R) space flight- transferrin, R antioxidant, calcium  (Ca) blocker -  magnesium, conducive to severe oxidative stress, Ca overload  with potential endothelial injuries. Using moon walker studies as example, my recent editorials show that I dust, released from brakes, with over 90% of brakes made of I, is a major hypertension factor and may  also contribute to myocardial infarctions.

Keynote Forum

William J. Rowe

Former Assistant Clinical Professor of Medicine, Medical University of Ohio at Toledo,USA

Keynote: Hypertension risk from iron brake particulate matter

Time : 9.00:9:45

Biography:

William J. Rowe M.D. FBIS (Fellow British Interplanetary Society), FACN (Fellow American College of Nutrition, Retired Fellow Royal Society of Medicine), is a board certified specialist in Internal Medicine. He received his M.D. at the University of Cincinnati and was in private practice in Toledo, Ohio for 34 years. This triggered a 20 year pursuit of the cardiovascular complications of Space flight. He has published in LANCET that extraordinary, unremitting endurance exercise can injure a perfectly normal heart. Of only 4 space syndromes, he has published 2: "The Apollo 15 Space Syndrome" and "Neil Armstrong Syndrome." 

Abstract:

Of 12 moon walkers, James Irwin on day after return from Apollo 15 mission, showed extraordinary bicycle ( B) stress test (ST) hypertension ( 275/125) after 3 minutes exercise; supervising > 5000  maximum treadmill  ST, author never witnessed ST- blood pressure approaching this level.  Symptom-limited maximum B stress test showed “cyanotic fingernails”; possibly venous blood trapped peripherally, supporting author’s “Apollo 15 Space Syndrome,” postulating that severe fingertip pain during space walks, triggered by plasma fluid, trapped distally;  mechanism could be related to endothelial dysfunction, providing “silent ischemia” warning.  Neil Armstrong returned to Earth with severe diastolic hypertension  ( 160/135), consistent with ischemic left ventricular dysfunction; 50 mm increase in comparison with resting  BP 110/85. With inhalation of lunar dust, brought into habitat on space suit, with high lunar iron (I) this dust inhalation, along with reduced (R) space flight- transferrin, R antioxidant, calcium  (Ca) blocker -  magnesium, conducive to severe oxidative stress, Ca overload  with potential endothelial injuries. Using moon walker studies as example, my recent editorials show that I dust, released from brakes, with over 90% of brakes made of I, is a major hypertension factor and may  also contribute to myocardial infarctions.

Keynote Forum

Samer H. Ellahham

Cleveland Clinic, USA and Cleveland Clinic Abu Dhabi, UAE

Keynote: The nuts and bolts of an inpatient cardio-oncology consult team

Time : 10.30-11.30

Conference Series Cardiology-2020 International Conference Keynote Speaker Samer H. Ellahham photo
Biography:

Dr. Ellahham received his undergraduate degree in biology and his M.D. from the American University of Beirut, Beirut, Lebanon. Dr Ellahham finished his internal medicine residency in Georgetown University Hospital - Washington Hospital Center and his fellowship in Cardiology at the Virginia Commonwealth University Health System in USA. Dr. Ellahham worked in Washington DC in Georgetown University Hospital - Washington Hospital Center and in several clinical and leadership positions before moving to UAE in 2008. Dr. Ellahham continues to be an active clinician. He demonstrates great skill and experience in the management of patients with heart failure, ischemic heart disease, and valvular heart disease and led a multi-disciplinary team in the care and delivery of advanced therapies to these patients. He has unique abilities to partner and engage local and regional referring providers. He can work in a highly matrixed environment, possess strong leadership and organizational skills and have experience to working effectively in a large health system. He led the First AHA GWTG Heart Failure Initiative outside US and was the recipient of the AHA GWTG Award in Wash. DC. He is the champion of the AHA GWTG in the region. Dr. Ellahham has served as Chief Quality Officer for SKMC from 2009 till 2017. In his role, he has led the development of a quality and safety program that has been highly successful and visible and has been recognized internationally by several awards. As Chief Quality Officer and Global Healthcare Leader, he had a focus on ensuring that implementation of these best practices leads to breakthrough improvements in clinical quality, patient safety, patient experience and risk management.

Abstract:

Cancer is a global burden. By the year 2030, 23.6 million new cancer cases are expected to be added annually to the global burden. Traditional cancer treatment such as anthracycline-based chemotherapies, monoclonal antibody-based therapies (e.g. trastuzumab), and radiation can have cardiac toxicities. In the last decade, novel cancer therapies or their combinations have improved cancer survivorship. These cancer therapies are associated with cardiovascular complications. Additionally, cancer patients and survivors are often elderly and have new or preexisting cardiovascular comorbidities. Patients with pre-existing cardiovascular disease have an increased risk of cardiovascular toxicity. Cardiovascular complications of cancer therapy have a profound negative effect on the survival and quality of life of cancer patients. Cancer therapies can affect the whole cardiovascular system but generally, these cardiotoxic effects are reported as changes in left ventricular (LV) ejection fraction. The most common cardiovascular adverse effects are LV dysfunction and heart failure (HF). Other adverse effects include hypertension, acute coronary syndromes, thromboembolic events, rhythm disturbances, valvular and/or pericardial disease. Hence, prediction, early recognition and timely management of cardiovascular complications in cancer patients is gaining importance. This need gave birth to the concept of interdisciplinary cardiology-oncology (cardio-onco) care delivered through a team of cardiologists, oncologists and hematologists. The cardio-onco care model is a relatively new field. Clinicians often face the dilemma as to whether give preference to the cancer status of the patient or to the cardiovascular toxicity. Lack of awareness about this integrated practice, its availability in very few centers, lack of proper protocols for decision making and resources to set up such a team are some of the key challenges in implementing the cardio-oncology program Oncologists, nurses, patients and their attendants should be trained to recognize signs and symptoms of cardiotoxicity.

 

Keynote Forum

Dr. Sudha Bansode

University of California, Riverside, USA.

Keynote: Heart disease

Time : 11.30-12.30

Conference Series Cardiology-2020 International Conference Keynote Speaker Dr. Sudha Bansode photo
Biography:

Dr. Sudha Bansode is a Associate Professor in Zoology at Shankarrao Mohite College, Akluj, Maharashtra State, India. Recently she has completed her Post Doctoral Studies at University of California, Riverside, USA. She is a active researcher & passionate teacher in India. Still she has been published above 35 research papers in International Journals & she is interested on Bone Research. Also she has honour of Distinguished Editorial Board Member of several International Journals. She is a own author of “Textbook Histological Techniques” & “Outlines of Physiology”. And now she is working on another own reference book “Rhythms in Freshwater Crustaceans”. She is a University recognized research guide for Ph.D. students in India.She was a invited Indian Speaker of “OXFORD SYMPOSIUM” on 27-29 August, 2014 at Balliol College, Oxford, United Kingdom & CELL SIGNALING & CANCER THERAPY – International Conference at Double Tree, Hilton Chicago on 27-28 September 2017, Genetics, Cell and Gene Therapy at Amsterdam, Netherlands, Sweden, Canada etc. She was academic visitor of Bangkok- Thailand, Colombo-Sri Lanka, Daira-Dubai-UAE. Her recent intellectual Interaction is with many International Professional groups.

Abstract:

There are many factors that can increase your risk of getting heart disease. Some of these factors are out of your control, but many of them can be avoided by choosing to live a healthy lifestyle. Some of the risk factors you cannot control are: Gender, Age, Family History, Obesity, High Cholesterol, Smoking, High Blood Pressure, Diabetes, Other factors.Heart disease is the leading cause of death.  The causes and prevention of heart disease have been studied for years, and new information is emerging. For the last several decades, saturated fat and cholesterol have been thought to be major contributors to coronary artery disease, and therefore people are typically advised to strictly limit these in their diet. However, recent studies are indicating that it may not be wise to strictly limit the intake of dietary saturated fatty acids or replace them with polyunsaturated fatty acids when taking other health conditions into consideration. Depending on a person’s genetics, diet may or may not be an important factor in preventing heart disease. Exercise is also beneficial for everyone in preventing heart disease. When considering human development, including the negative effects of heart disease, humans still have a lot to learn about the human body and the interaction of diet, the environment, and genetics.

  • Heart Diseases|Women’s Cardiovascular Health|Cardio Oncology
Location: Amsterdam

Session Introduction

Ramachandran Muthiah

Professor Dr.SMCSI Mission hospital & Medical college INDIA

Title: Taussig-bing heart
Speaker
Biography:

Ramachandran Muthiah, Consultant Physician & Cardiologist, Zion hospital, Azhagiamandapam, Kanyakumari District, India. Completed M.D. in General Medicine in 1996, D.M. in cardiology in 2003 under Tamil Nadu Dr.MGR Medical University, Chennai, India. Worked as medical officer in Rural health services for 5 years and in teaching category as Assistant Professor at Madras medical college, Coimbatore medical college, Thoothukudi medical college and Professor at Dr.SMCSI Mission hospital & Medical college, Karakonam, Trovandrum and Azeezia Medical college, Kollam. Published many papers in Cardiosource, American College of Cardiology Foundation, Case Reports in Clinical Medicine (SCIRP) and Journal of Saudi Heart Association. Special research on Rheumatic fever and Endomyocardial fibrosis in tropical belts, Myxomas, Ineffective endocarditis, apical hypertrophic cardiomyopathy, Ebstein’s anomaly, Rheumatic Taussig-Bing Heart, Costello syndrome and Tetralogy of Fallot.

Abstract:

Taussig-Bing heart is one of the conotruncal malformations. Embryologically, abnormal cardiac looping with misalignment of conotruncal septum result its complexity and great artery relationships. It was first described in 1949 by two outstanding physicians, Helen Brooke Taussig and Richard John Bing, who worked together at the John Hopkins Hospital in Baltimore. The original “Taussig-Bing heart” may be summarized as a double-outlet right ventricle (DORV) with semilunar valves side-by-side and approximately at the same height, bilateral conus, and a subpulmonary VSD. This original description has been broadened to include all kinds of double-outlet right ventricle with subpulmonary VSD. The evolution of surgical repair for the Taussig-Bing anomaly has progressed from atrial baffle procedures to arterial switch with VSD closure and intraventricular repair. For patients with Taussig-Bing type of DORV, the “arterial switch” operation, first reported in 1981, still appears to be the procedure of choice and can be performed in the neonatal period and also in patients with all types of great artery anatomy without ventriculotomy.

Break: 12.30-1.30

Samer Ellahham

Cleveland Clinic, US and Cleveland Clinic Abu Dhabi, UAE

Title: Update on nutrition in chronic heart failure
Speaker
Biography:

Dr. Ellahham received his undergraduate degree in biology and his M.D. from the American University of Beirut, Beirut, Lebanon. Dr Ellahham finished his internal medicine residency in Georgetown University Hospital - Washington Hospital Center and his fellowship in Cardiology at the Virginia Commonwealth University Health System in USA. Dr. Ellahham worked in Washington DC in Georgetown University Hospital - Washington Hospital Center and in several clinical and leadership positions before moving to UAE in 2008. Dr. Ellahham continues to be an active clinician. He demonstrates great skill and experience in the management of patients with heart failure, ischemic heart disease, and valvular heart disease and led a multi-disciplinary team in the care and delivery of advanced therapies to these patients. He has unique abilities to partner and engage local and regional referring providers. He can work in a highly matrixed environment, possess strong leadership and organizational skills and have experience to working effectively in a large health system. He led the First AHA GWTG Heart Failure Initiative outside US and was the recipient of the AHA GWTG Award in Wash. DC. He is the champion of the AHA GWTG in the region. Dr. Ellahham has served as Chief Quality Officer for SKMC from 2009 till 2017. In his role, he has led the development of a quality and safety program that has been highly successful and visible and has been recognized internationally by several awards. As Chief Quality Officer and Global Healthcare Leader, he had a focus on ensuring that implementation of these best practices leads to breakthrough improvements in clinical quality, patient safety, patient experience and risk management.

Abstract:

Chronic heart failure is defined as decreased ability of heart due to variousreasons.Despite improvements in pharmacologic treatment, many patients with heart failure have severe and persistent symptoms, and their prognosis remains poor. The objectives of nutrition therapy in heart failure are to prevent from water retention and edema, to avoid from hard digestion and to offer a balanced diet. To avoid fluid retention and edema, daily sodium and fluid intake must be monitored carefully. Main dilemma of the heart failure patients is the obesity-cachexia dilemma. Since one of the main reasons of heart failure is cardiovascular diseases, in first phase, the patient may be obese. In the later phases, cachexia may show up. It was shown that cachexia is associated with mortality. Within this period, patients should not be over-fed and the patient should pass from catabolic state to anabolic state slowly. If the gastrointestinal track is functional oral/enteral feeding must be preferred. Large, controlled and well-designed studies must be conducted to evaluate the benefits of nutritional practices such as nutritional assessment, enteral feeding and nutrient supports in heart failure patients.

 

 

Yacob Mathai

Marma Heatth Centre,Kochi ,Kerala,India

Title: The pyrexia temperature never damage the cells of brain or harm the body.
Speaker
Biography:

K. M. Yacob  practicing physician in the field of healthcare in the state of Kerala in India for the last 30 years and very much interested in basic research. My interest is spread across the fever , inflammation and  back pain,. I am a writer. I already printed and published nine books in these subjects. I wrote hundreds of articles in various magazines.After scientific studies we have developed 8000 affirmative cross checking questions. It  can explain all queries related with fever.

Abstract:

All treatments for fever are based on the belief  that  fits is the result of  41 degree Celsius temperature and  it  damages cells of  brain and body. At the same time there is no evidence based   tests or concrete  diagnosing  methods  to the  belief  that  fits and brain damage  is the result of  pyrexia [1].Necessary ingredients to destroy brain cells  and fits cannot be seen  in fever.In pyrexia or absence of fever  a fainted  patient fell on the floor with unconscious state and destroy cells of brain, and necessary ingredients to  become conscious are same.When disease increases essential blood circulation and energy level also decreases. The vertical height between heart and brain is more than one feet. When the disease becomes severe, ability to pump the  blood to the brain decreases. As a result of this   brain cells are damaged. so the patient might be paralyzed or may even die.In pyrexia or absence of fever,  when blood flow to the brain decreases and fits are formed. There is no other  way than  this  to increase  blood circulation  to the brain.It is  a sensible and discreet  action of brain to protect the  life or organ. 

Recovery from  Fits.The patient become conscious before the time to get decreasing the temperature of fever. When the fainted patient lie on the floor, the vertical height between heart and brain is decreased, blood circulation increased to brain.

 Self checking  methods.When the fainted patient lie on the floor,The patient can stand straight and lie on bed alternatively.Then the patient can experience  himself the intensity of blood circulation.T he patient can experience when he stand  his blood circulation decreases and when lie on the bed the blood circulation decreases.Besides that he can also experience increased blood circulation when lie on the bed raise the foot higher than head.

Dr. Remya Sudevan

Amrita Institute of Medical Sciences, Kochi,India

Title: Use of cardiovascular drugs in the compliance of secondary prevention of coronary artery disease- Hospital based multicentric cross sectional survey

Time : 3.30-4.30

Biography:

Dr. Remya Sudevan is pursuing her PHD in Preventive cardiology at Amrita Institute of Medical Sciences, Kochi .She is currently in the 4th year of her PhD program. She has completed her MBBS and post graduate diploma in Developmental paediatrics from Government Medical college, Thiruvananthapuram, Kerala. She has diploma in Diabetology. She is trained in clinical research from Mc Master University, Hamilton, Canada. She has Masters in Public health from Sree Chitra Tirunal  Institute of  Medical sciences and technology, Thiruvananthapuram. She has 6 years experience as Clinical epidemiologist. She has more than 50 publications including abstracts.     

Abstract:

Among the mandatory targets to be achieved in the compliance of secondary prevention of coronary artery disease, cardiovascular drug use has a pivotal role.  There exists scarcity of data regarding the use of these drugs in coronary artery disease (CAD) patients from resource limited settings. Existing guidelines recommend drug therapy using antiplatelet, lipid lowering drugs, renin angiotensin aldosterone system inhibitors, betablockers, insulin and oral hypoglycaemic agents in diabetics for secondary prevention of CAD. A multi centric hospital based cross sectional survey was done in a total of 1206 patients with confirmed CAD diagnosed during the time period January 2012-December 2018.The objective was to estimate the proportion of compliance to use of cardiovascular drugs. The mean age of the study population was 61.27(9.59) years. In the study population, 879(72.9%) were male patients. The socio economic status was predominantly in the middle (48.1%) and low (48.9%) levels. In the study population, 43% had a family history of heart attack, 64.2% had hypertension, 54.1% had diabetes mellitus, 52% had dyslipidemia, 5.8% had smoking/use of tobacco and 2.8% consumed alcohol. The treatment strategies adopted were medical therapy (44.8%), angioplasty (47.8%) and coronary artery bypass grafting (12.9%). The proportion of patients on cardiovascular drugs were 96.02% on antiplatelets, 89.4% statins, 37.72% on RAAS, 68.2% on betablockers, 22% on insulin and 81.28% on oral hypoglycaemic agents(Table 1). Use of cardiovascular drugs in secondary prevention of CAD patients in resource limited setting appears to be satisfactory.